Baillie Gifford & Co’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$72.7M	Sell	23,675,407 -99,565	-0.4%	-$385K	0.07%	136
2025 Q4	$97.2M	Sell	23,774,972 -203,723	-0.8%	-$1.01M	0.08%	127
2025 Q3	$117M	Sell	23,978,695 -195,120	-0.8%	-$1.02M	0.09%	122
2025 Q2	$122M	Sell	24,173,815 -219,200	-0.9%	-$1.08M	0.09%	122
2025 Q1	$129M	Sell	24,393,015 -471,043	-2%	-$3.43M	0.11%	116
2024 Q4	$168M	Sell	24,864,058 -375,812	-1%	-$2.53M	0.13%	110
2024 Q3	$166M	Sell	25,239,870 -1,350,066	-5%	-$9.68M	0.12%	106
2024 Q2	$199M	Buy	26,589,936 +2,522,132	+10%	+$22M	0.16%	95
2024 Q1	$240M	Sell	24,067,804 -111,700	-0.5%	-$1.24M	0.19%	93
2023 Q4	$238M	Sell	24,179,504 -371,905	-2%	-$2.65M	0.19%	98
2023 Q3	$188M	Sell	24,551,409 -546,221	-2%	-$5.45M	0.17%	95
2023 Q2	$187M	Sell	25,097,630 -37,900	-0.2%	-$265K	0.16%	101
2023 Q1	$168M	Buy	25,135,530 +314,680	+1%	+$2.5M	0.15%	102
2022 Q4	$191M	Buy	24,820,850 +3,226,157	+15%	+$31.6M	0.2%	92
2022 Q3	$230M	Sell	21,594,693 -10,992	-0.1%	-$111K	0.24%	85
2022 Q2	$176M	Sell	21,605,685 -375,919	-2%	-$2.52M	0.18%	94
2022 Q1	$157M	Sell	21,981,604 -141,551	-0.6%	-$1.5M	0.11%	112
2021 Q4	$379M	Buy	22,123,155 +61,781	+0.3%	+$1.16M	0.21%	88
2021 Q3	$508M	Buy	22,061,374 +3,540,374	+19%	+$100M	0.27%	83
2021 Q2	$676M	Buy	+18,521,000	New	+$548M	0.33%	79